India's first transgender clinics close after USAID freeze
US President Donald Trump ordered a 90-day pause on all foreign aid in January pending a review to ensure all projects funded with U.S. taxpayer money are aligned with his "America First" policy.
Trump has repeatedly criticised what he called USAID spending $21 million on "voter turnout" in India. The Indian government said last week it was investigating.
Among the main losers following the fund freeze have been three Mitr (friend) Clinics in India that are run mostly by doctors, counsellors and other workers from the transgender community and that serve up to 5,000 people, said the sources. Both declined to be named, citing the sensitivity of the matter.
Trump ally Elon Musk and Republican Senator John Kennedy have both criticised the transgender funding.
"That's what American tax dollars were funding," Musk said on X on Friday in response to a post about the closure of the first of the Mitr clinics, launched in the southern Indian city of Hyderabad in 2021.
The other clinics are located in the western cities of Kalyan and Pune.
All provided services including guidance and medication on hormone therapy, counselling on mental health as well as on HIV and other sexually transmitted diseases, and legal aid, in addition to general medical care, a website for the three clinics said.
Each of them needed up to Rs3 million ($34,338) a year to run and employed about eight people, said one of the sources, adding that they were looking for alternate sources of funding, public or private.
Organisers of the clinics, however, have got a waiver from USAID to keep running certain life-saving activities, including providing antiretroviral medication to HIV-infected people, the sources said.
Up to 10% of all clinic clients are infected by HIV, one of the sources said.
"We did some really good work at Mitr Clinics," said one of the sources, a doctor. "I am proud of what we achieved there."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
a day ago
- Gulf Today
5 years after COVID, pharma shares languish
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative US market and potential 200% tariffs on pharma imports into the US. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved, reported Reuters. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying US policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs, Reuters reported. Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of US rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up — yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, US healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference.
Khaleej Times
3 days ago
- Khaleej Times
Coca-Cola plans US cane sugar alternative after Trump push
Coca-Cola on Tuesday said it would release a version of Coke in the United States made with US-grown real cane sugar, a move requested by President Donald Trump. "We're going to be bringing a Coke sweetened with US cane sugar into the market this fall, and I think that will be an enduring option for consumers," said CEO James Quincey on a call with analysts. The company currently uses high-fructose corn syrup (HFCS) for many of its US products — a sweetener that has long drawn criticism from Health Secretary Robert F. Kennedy Jr. and his "Make America Healthy Again" agenda. Trump last week said that the company had agreed to use cane sugar in the United States version of Coke. "This will be a very good move by them — You'll see. It's just better!" Trump wrote on Truth Social. Coca-Cola at the time did not confirm the move even if it said it appreciated Trump's "enthusiasm" for its brand. In announcing the new option, Quincey insisted that the main Coke product would still be made with corn syrup, with the cane sugar version offered as an alternative. Mexican Coke — which is made with cane sugar — is often sold at a premium in US stores and prized for its more "natural" flavour. The US president did not explain what motivated his push for the change, which would not impact his well-known favorite beverage, Diet Coke. Since his return to the White House, Trump has reinstalled a special button in the Oval Office that summons a helping of the sugar-free carbonated drink. HFCS became popular in the 1970s, with its use skyrocketing thanks to government subsidies for corn growers and high import tariffs on cane sugar. Any shift away from corn is likely to draw backlash in the Corn Belt, a Midwestern region that has been a stronghold of support for Trump. Both HFCS and sucrose (cane sugar) are composed of fructose and glucose, but differ at the structural level. Those differences don't appear to significantly affect health outcomes, according to research. Trump's preferred Diet Coke is sweetened with aspartame — a compound classified as a "possible carcinogen" by the International Agency for Research on Cancer (IARC).
Al Etihad
4 days ago
- Al Etihad
AstraZeneca says to invest $50 billion in the US
22 July 2025 11:25 LONDON (AFP)British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington.A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030."Today's announcement underpins our belief in America's innovation in biopharmaceuticals," the statement quoted CEO Pascal Soriot as President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to his sweeping levies on imports from trading ordered an investigation launched into pharmaceutical imports, suggesting that levies could reach up to 200 United States is a key market for the pharmaceutical industry, and AstraZeneca had already announced in April that it had begun transferring part of its European production to the United States. "For decades Americans have been reliant on foreign supply of key pharmaceutical products," US Commerce Secretary Howard Lutnick said in a added that the new tariffs are focused on "ending this structural weakness."The announcement included a new factory in Virginia, which will be the company's "largest single manufacturing investment." Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have, in recent months, begun shifting investment and production to the United States.
